Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Morphine sulphate tablets in hospice practice.

J D Bonifant1, M Clark-Reynolds

  • 1Mary Potter Hospice, Wellington, New Zealand.

Postgraduate Medical Journal
|January 1, 1991
PubMed
Summary

Sustained release morphine sulphate tablets (MST) are effective and well-tolerated for pain management in palliative and terminal care. This study confirms MST

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Hallerman-Strieff syndrome. Case report.

The New Zealand medical journalยท1969
See all related articles

Area of Science:

  • Palliative Care
  • Pain Management
  • Pharmacology

Background:

  • Sustained release morphine sulphate tablets (MST Continus) have been used in New Zealand since 1984.
  • MST has become a primary opioid for palliative and terminal care.
  • The Mary Potter Hospice, established in 1978, is New Zealand's largest hospice.

Purpose of the Study:

  • To document current hospice usage of MST.
  • To assess the efficacy and tolerability of MST in palliative care patients.
  • To identify reasons for MST cessation.

Main Methods:

  • Prospective collection of records for 100 consecutive patients prescribed MST.
  • Analysis of patient data within the Mary Potter Hospice Programme.
  • Documentation of MST dosage, reasons for use, and cessation.

Main Results:

  • MST was widely tolerated and highly successful in controlling pain for most patients.
  • Dosage requirements varied widely and were independent of pathology, age, or prior analgesic exposure.
  • Inappropriate MST use was readily identifiable.
  • Common reasons for stopping MST were patient death or moribund state, not nausea, vomiting, confusion, or altered consciousness.

Conclusions:

  • MST is a highly effective and well-tolerated opioid for pain management in palliative and terminal care.
  • Current hospice usage demonstrates the advantages of MST in this setting.
  • The study provides evidence supporting MST's role as a principal opioid in palliative and terminal care.

Related Experiment Videos